NephrologyANCA-Associated VasculitisPEXIVAS trial
Predicting Two-Year Relapse Risk in ANCA-Associated Vasculitis: Insights from the PEXIVAS Trial
By MedXY|Oct 2, 2026
A risk prediction model derived from the PEXIVAS trial estimates the 2-year relapse probability in ANCA-associated vasculitis, integrating clinical and laboratory factors to improve individualized patient management.